$2.26 Billion is the total value of Nantahala Capital Management's 122 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 29.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNL | Sell | TRAVEL PLUS LEISURE COcall | $53,253,000 | -3.6% | 919,100 | -8.1% | 2.36% | +21.1% |
| IMAX | Sell | IMAX CORP | $50,513,000 | +1.2% | 2,668,431 | -4.6% | 2.24% | +27.3% |
| TNL | Sell | TRAVEL PLUS LEISURE CO | $50,261,000 | -3.4% | 867,464 | -7.8% | 2.22% | +21.5% |
| CASH | Sell | META FINL GROUP INC | $47,780,000 | -10.6% | 869,993 | -2.9% | 2.11% | +12.4% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $46,792,000 | -25.0% | 2,692,303 | -5.6% | 2.07% | -5.7% |
| IMAX | Sell | IMAX CORPcall | $41,481,000 | -3.1% | 2,191,300 | -8.7% | 1.84% | +21.8% |
| GDEN | Sell | GOLDEN ENTMT INC | $40,103,000 | -25.9% | 690,606 | -35.5% | 1.77% | -6.9% |
| DXPE | Sell | DXP ENTERPRISES INC | $32,215,000 | +2.6% | 1,189,179 | -2.8% | 1.42% | +29.0% |
| RMR | Sell | RMR GROUP INCcl a | $29,914,000 | -10.5% | 961,851 | -0.2% | 1.32% | +12.5% |
| IMXI | Sell | INTERNATIONAL MNY EXPRESS IN | $29,390,000 | +14.3% | 1,425,985 | -11.5% | 1.30% | +43.6% |
| PTON | Sell | PELOTON INTERACTIVE INCcall | $23,477,000 | -27.1% | 888,600 | -1.3% | 1.04% | -8.2% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $22,536,000 | -28.9% | 3,724,899 | -1.0% | 1.00% | -10.7% |
| XBI | Sell | SPDR SER TRput | $22,470,000 | -69.1% | 250,000 | -61.5% | 0.99% | -61.2% |
| ALTG | Sell | ALTA EQUIPMENT GROUP INC | $22,330,000 | -21.6% | 1,806,607 | -7.2% | 0.99% | -1.5% |
| QURE | Sell | UNIQURE NVcall | $16,082,000 | -63.2% | 890,000 | -57.7% | 0.71% | -53.7% |
| BBQ | Sell | BBQ HLDGS INC | $14,407,000 | -9.0% | 951,559 | -4.8% | 0.64% | +14.4% |
| RDI | Sell | READING INTL INCcl a | $13,810,000 | -1.7% | 3,226,656 | -7.2% | 0.61% | +23.7% |
| FBIO | Sell | FORTRESS BIOTECH INC | $12,026,000 | -47.1% | 8,842,525 | -2.7% | 0.53% | -33.4% |
| CUE | Sell | CUE BIOPHARMA INC | $10,952,000 | -61.9% | 2,244,359 | -11.6% | 0.48% | -52.0% |
| Sell | APTOSE BIOSCIENCES INC | $9,958,000 | -3.0% | 7,322,189 | -3.7% | 0.44% | +22.2% | |
| IIII | Sell | INSU ACQUISITION CORP III | $9,773,000 | -0.3% | 995,173 | -0.5% | 0.43% | +25.2% |
| FTCV | Sell | FINTECH ACQUISITION CORP V | $9,457,000 | -3.8% | 958,137 | -3.4% | 0.42% | +20.8% |
| TSHA | Sell | TAYSHA GENE THERAPIES INC | $8,697,000 | -48.7% | 1,333,947 | -8.4% | 0.38% | -35.5% |
| Sell | ARYA SCIENCES ACQUISITN CORP | $8,423,000 | -13.1% | 865,633 | -13.4% | 0.37% | +9.4% | |
| SFT | Sell | SHIFT TECHNOLOGIES INCcl a | $8,208,000 | -41.5% | 3,730,912 | -9.4% | 0.36% | -26.5% |
| HLF | Sell | HERBALIFE NUTRITION LTDcall | $8,127,000 | -28.6% | 267,700 | -3.7% | 0.36% | -10.0% |
| HERA | Sell | FTAC HERA ACQUISITION CORP | $7,832,000 | -13.9% | 800,001 | -14.1% | 0.35% | +8.4% |
| SRL | Sell | SCULLY ROYALTY LTD | $7,585,000 | +6.1% | 772,437 | -4.3% | 0.34% | +33.3% |
| Sell | PAR TECHNOLOGY CORPnote 2.875% 4/1 | $6,953,000 | -21.2% | 5,785,000 | -3.6% | 0.31% | -0.6% | |
| VMD | Sell | VIEMED HEALTHCARE INC | $6,443,000 | -13.3% | 1,293,812 | -9.1% | 0.28% | +9.2% |
| Sell | AKUMIN INC | $6,193,000 | -44.0% | 5,578,992 | -11.7% | 0.27% | -29.6% | |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $5,890,000 | -12.9% | 1,893,997 | -5.3% | 0.26% | +9.7% |
| RILY | Sell | B. RILEY FINANCIAL INC | $5,492,000 | -33.8% | 78,508 | -15.9% | 0.24% | -16.8% |
| Sell | AVALO THERAPEUTICS INC | $4,804,000 | -60.5% | 6,849,547 | -4.1% | 0.21% | -50.1% | |
| CDTX | Sell | CIDARA THERAPEUTICS INC | $4,126,000 | -38.4% | 4,954,882 | -6.0% | 0.18% | -22.1% |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $3,878,000 | -27.3% | 893,561 | -13.2% | 0.17% | -8.5% |
| KURA | Sell | KURA ONCOLOGY INCcall | $3,874,000 | +10.7% | 240,900 | -3.6% | 0.17% | +39.0% |
| Sell | HELIOGEN INC | $3,385,000 | -71.8% | 643,599 | -17.0% | 0.15% | -64.5% | |
| MACK | Sell | MERRIMACK PHARMACEUTICALS IN | $3,269,000 | +46.7% | 516,817 | -9.3% | 0.14% | +85.9% |
| ARYD | Sell | ARYA SCIENCES ACQU CORP IVcl a | $3,193,000 | -19.3% | 325,848 | -18.4% | 0.14% | +1.4% |
| SBTX | Sell | SILVERBACK THERAPEUTICS INC | $3,152,000 | -53.0% | 913,597 | -9.2% | 0.14% | -41.1% |
| BRPM | Sell | B RILEY PRINCIPAL 150 MERGER | $2,994,000 | -15.4% | 301,786 | -13.7% | 0.13% | +6.5% |
| IMV | Sell | IMV INC | $2,632,000 | +5.0% | 1,866,491 | -9.2% | 0.12% | +31.8% |
| ANGN | Sell | ANGION BIOMEDICA CORP | $2,487,000 | -32.3% | 1,173,162 | -7.4% | 0.11% | -14.7% |
| IMAC | Sell | IMAC HLDGS INC | $2,308,000 | -15.4% | 2,241,113 | -6.3% | 0.10% | +6.2% |
| ACER | Sell | ACER THERAPEUTICS INC | $2,256,000 | +9.8% | 777,820 | -13.7% | 0.10% | +38.9% |
| ZVO | Sell | ZOVIO INC | $2,144,000 | -43.4% | 2,613,763 | -12.3% | 0.10% | -28.6% |
| SLNO | Sell | SOLENO THERAPEUTICS INC | $2,104,000 | -47.5% | 9,436,512 | -3.4% | 0.09% | -34.0% |
| Sell | HYPERFINE INC | $2,112,000 | -59.5% | 596,480 | -17.0% | 0.09% | -49.2% | |
| IDWM | Sell | IDW MEDIA HLDGS INCcl b | $2,047,000 | -16.7% | 1,118,406 | -9.0% | 0.09% | +5.8% |
| IMTXW | Sell | IMMATICS N.V*w exp 07/01/202 | $1,740,000 | -63.0% | 1,035,613 | -3.3% | 0.08% | -53.3% |
| PAYO | Sell | PAYONEER GLOBAL INC | $1,719,000 | -41.3% | 385,366 | -3.3% | 0.08% | -26.2% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $1,638,000 | -42.5% | 819,101 | -9.7% | 0.07% | -28.0% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $1,598,000 | -36.7% | 2,420,789 | -12.3% | 0.07% | -20.2% |
| FVAM | Sell | 5 01 ACQUISITION CORP | $1,600,000 | -10.7% | 162,430 | -10.7% | 0.07% | +12.7% |
| LVTX | Sell | LAVA THERAPEUTICS NV | $1,470,000 | -25.9% | 334,164 | -7.4% | 0.06% | -7.1% |
| MILE | Sell | METROMILE INC | $1,377,000 | -43.8% | 1,043,514 | -6.8% | 0.06% | -29.1% |
| XGN | Sell | EXAGEN INC | $1,279,000 | -41.2% | 159,253 | -14.8% | 0.06% | -25.0% |
| Sell | IN8BIO INC | $1,226,000 | -25.2% | 352,753 | -5.5% | 0.05% | -6.9% | |
| Sell | LUCID DIAGNOSTICS INC | $1,060,000 | -54.6% | 315,414 | -27.5% | 0.05% | -42.7% | |
| Sell | UNICYCIVE THERAPEUTICS INC | $826,000 | -41.6% | 640,633 | -6.7% | 0.04% | -26.0% | |
| Sell | TANGO THERAPEUTICS INC | $749,000 | -31.5% | 98,794 | -1.2% | 0.03% | -13.2% | |
| AKBA | Sell | AKEBIA THERAPEUTICS INCcall | $693,000 | -69.3% | 965,800 | -3.4% | 0.03% | -61.2% |
| Sell | COGNITION THERAPEUTICS INC | $540,000 | -59.2% | 196,402 | -6.3% | 0.02% | -48.9% | |
| TACT | Sell | TRANSACT TECHNOLOGIES INC | $504,000 | -39.6% | 71,335 | -6.9% | 0.02% | -24.1% |
| ELOX | Sell | ELOXX PHARMACEUTICALS INC | $434,000 | -31.3% | 774,767 | -13.4% | 0.02% | -13.6% |
| HTGM | Sell | HTG MOLECULAR DIAGNOSTICS IN | $397,000 | -78.1% | 285,963 | -14.6% | 0.02% | -71.9% |
| GLMD | Sell | GALMED PHARMACEUTICALS LTD | $412,000 | -24.0% | 258,957 | -13.1% | 0.02% | -5.3% |
| Sell | FALCON MINERALS CORP*w exp 07/21/202 | $256,000 | +109.8% | 674,561 | -23.2% | 0.01% | +175.0% | |
| Sell | GUARDFORCE AI CO LTD*w exp 10/01/202 | $142,000 | -57.4% | 374,205 | -37.6% | 0.01% | -50.0% | |
| BRPMW | Sell | B RILEY PRINCIPAL 150 MERGER*w exp 03/01/202 | $109,000 | -39.8% | 120,686 | -3.4% | 0.01% | -16.7% |
| HERAW | Sell | FTAC HERA ACQUISITION CORP*w exp 02/28/202 | $97,000 | -59.1% | 222,949 | -10.8% | 0.00% | -50.0% |
| MILEW | Sell | METROMILE INC*w exp 02/09/202 | $66,000 | -15.4% | 507,460 | -9.1% | 0.00% | 0.0% |
| OCGN | Sell | OCUGEN INC | $55,000 | -81.0% | 16,571 | -73.9% | 0.00% | -80.0% |
| BRPMU | Exit | B RILEY PRINCIPAL 150 MERGERunit 99/99/9999 | $0 | – | -9 | -100.0% | 0.00% | – |
| HERAU | Exit | FTAC HERA ACQUISITION CORPunit 02/28/2026 | $0 | – | -9 | -100.0% | 0.00% | – |
| IIIIU | Exit | INSU ACQUISITION CORP IIIunit 12/31/2026 | $0 | – | -4 | -100.0% | 0.00% | – |
| ROCRW | Exit | ROTH CH ACQUISITION III CO*w exp 02/26/202 | $0 | – | -99,749 | -100.0% | -0.00% | – |
| Exit | BAKKT HOLDINGS INC | $0 | – | -52,499 | -100.0% | -0.02% | – | |
| HOOK | Exit | HOOKIPA PHARMA INC | $0 | – | -473,566 | -100.0% | -0.04% | – |
| ATXI | Exit | AVENUE THERAPEUTICS INC | $0 | – | -1,453,166 | -100.0% | -0.05% | – |
| CABA | Exit | CABALETTA BIO INC | $0 | – | -341,538 | -100.0% | -0.05% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -475,467 | -100.0% | -0.13% | – |
| BGFV | Exit | BIG 5 SPORTING GOODS CORPput | $0 | – | -200,000 | -100.0% | -0.13% | – |
| ZGNX | Exit | ZOGENIX INCcall | $0 | – | -236,400 | -100.0% | -0.14% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -0.15% | – |
| SPCE | Exit | VIRGIN GALACTIC HOLDINGS INCcall | $0 | – | -400,000 | -100.0% | -0.19% | – |
| PRTY | Exit | PARTY CITY HOLDCO INCcall | $0 | – | -1,000,000 | -100.0% | -0.20% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCcall | $0 | – | -300,000 | -100.0% | -0.25% | – |
| LINC | Exit | LINCOLN EDL SVCS CORP | $0 | – | -1,003,024 | -100.0% | -0.26% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -481,782 | -100.0% | -0.28% | – |
| TDOC | Exit | TELADOC HEALTH INCput | $0 | – | -100,000 | -100.0% | -0.32% | – |
| FTVIU | Exit | FINTECH ACQUISITION CORP VIunit 06/24/2026 | $0 | – | -1,000,000 | -100.0% | -0.35% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -4,918,565 | -100.0% | -0.39% | – |
| Exit | FALCON MINERALS CORP | $0 | – | -2,374,707 | -100.0% | -0.41% | – | |
| Exit | ZOGENIX INCnote 2.750%10/0 | $0 | – | -14,000,000 | -100.0% | -0.49% | – | |
| SWAV | Exit | SHOCKWAVE MED INCput | $0 | – | -80,000 | -100.0% | -0.50% | – |
| SC | Exit | SANTANDER CONSUMER USA HLDGS | $0 | – | -395,176 | -100.0% | -0.58% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -400,000 | -100.0% | -1.58% | – |
| CVNA | Exit | CARVANA COcall | $0 | – | -203,700 | -100.0% | -1.66% | – |
| THC | Exit | TENET HEALTHCARE CORPcall | $0 | – | -875,900 | -100.0% | -2.52% | – |
| SGMS | Exit | SCIENTIFIC GAMES CORPcall | $0 | – | -1,559,300 | -100.0% | -3.67% | – |
| W | Exit | WAYFAIR INCcall | $0 | – | -807,700 | -100.0% | -5.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
About Nantahala Capital Management
Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.
Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.
Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.
Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 42 | Q3 2023 | 27.2% |
| CODEXIS INC | 42 | Q3 2023 | 3.9% |
| PATHWARD FINANCIAL INC | 35 | Q3 2023 | 6.3% |
| SCIENTIFIC GAMES CORP | 34 | Q3 2022 | 5.3% |
| DOVER MOTORSPORTS INC | 34 | Q3 2021 | 0.5% |
| GOLDEN ENTMT INC | 33 | Q3 2023 | 2.1% |
| QAD INC | 32 | Q3 2021 | 2.6% |
| SCIENTIFIC GAMES CORP | 31 | Q4 2021 | 7.7% |
| DOLBY LABORATORIES INC | 31 | Q4 2020 | 5.6% |
| LINCOLN EDL SVCS CORP | 31 | Q4 2021 | 0.7% |
View Nantahala Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AYTU BIOPHARMA, INC | June 16, 2023 | 1,086,812 | 19.7% |
| Acer Therapeutics Inc. | February 14, 2023 | 1,226,191 | 7.5% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 4,611,302 | 7.5% |
| AKUMIN INC. | February 14, 2023 | 2,206,960 | 2.5% |
| ALTA EQUIPMENT GROUP INC. | February 14, 2023 | 1,188,985 | 3.7% |
| Apollo Endosurgery, Inc. | February 14, 2023 | 4,056,627 | 9.9% |
| Autolus Therapeutics plc | February 14, 2023 | 7,782,018 | 4.7% |
| Bioventus Inc. | February 14, 2023 | 3,168,574 | 5.1% |
| CATALYST BIOSCIENCES, INC. | February 14, 2023 | 438,055 | 1.4% |
| Drive Shack Inc. | February 14, 2023 | 6,500,000 | 7.0% |
View Nantahala Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-21 |
| 4 | 2024-03-15 |
| SC 13G | 2024-03-11 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Nantahala Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.